Related Experiment Videos
Lovastatin and coadministered antihypertensive/cardiovascular agents
Insights
Lovastatin effectively lowers LDL cholesterol in patients with hypertension, regardless of their antihypertensive medication. This study found no significant safety concerns or reduced efficacy when lovastatin was used with common blood pressure drugs.
Area of Science:
- Cardiovascular Pharmacology
- Clinical Lipidology
Background:
- Hypertension and hypercholesterolemia often coexist, necessitating combination drug therapy.
- Evaluating drug interactions is crucial for safe and effective treatment of comorbid conditions.
Purpose of the Study:
- To assess the efficacy and safety of lovastatin in hypercholesterolemic patients concurrently treated with various antihypertensive medications.
- To determine if antihypertensive agents affect lovastatin's lipid-lowering capabilities or safety profile.
Main Methods:
- Analysis of patient subgroups from the Expanded Clinical Evaluation of Lovastatin (EXCEL) Study (n=8,245).
- Comparison of lovastatin (20-80 mg daily) vs. placebo over 48 weeks.
- Subgroup analysis based on concomitant antihypertensive drug classes (calcium antagonists, beta-blockers, diuretics, ACE inhibitors).
Main Results:
- Lovastatin's LDL cholesterol-lowering effect was not diminished in any antihypertensive subgroup.
- A slight, borderline significant enhancement in LDL reduction was observed with calcium antagonists.
- No consistent differences in HDL cholesterol or triglyceride changes were noted across subgroups.
- No significant safety concerns or adverse event interactions were identified.
Conclusions:
- Lovastatin demonstrates consistent efficacy in lowering LDL cholesterol in patients with hypertension, irrespective of their antihypertensive regimen.
- The safety profile of lovastatin appears unaffected by common antihypertensive medications.
- Concomitant use of lovastatin with antihypertensives is a viable therapeutic option for managing comorbid hypercholesterolemia and hypertension.
Abstract:
Hypertension and hypercholesterolemia frequently coexist and may require concomitant drug treatments. The efficacy and safety profile of lovastatin given in the presence of antihypertensive medication was evaluated using patient subgroups identified in the Expanded Clinical Evaluation of Lovastatin (EXCEL) Study. The EXCEL study examined 8,245 patients with moderate hypercholesterolemia randomly assigned either to a group treated with lovastatin (20-80 mg daily) or to a group given placebo for 48 weeks. After adjustment for patient characteristics, pairwise comparisons were made between patients taking no antihypertensive agents (n = 3,772) and those taking either calcium antagonists (n = 446), selective beta 1-adrenergic receptor blockers (n = 326), nonselective beta-adrenergic receptor blockers (n = 219), potassium-sparing diuretics (n = 187), thiazide diuretics (n = 126), or angiotensin converting enzyme inhibitors (n = 171). The placebo-corrected dose-dependent effect of lovastatin on the percent change from baseline in low-density lipoprotein cholesterol was not attenuated in any subgroup and was slightly enhanced in the calcium antagonist subgroup (-29% to -44%, p = 0.06) when compared with patients taking no antihypertensive agents (-24% to -40%); this difference, however, was only of borderline significance. Patterns of lovastatin-induced increase in high-density lipoprotein cholesterol and decrease in triglycerides were not consistently different among the subgroups. Examination of mean changes in serum transaminases, mean changes in creatine kinase, and the proportion of patients discontinuing therapy for clinical adverse experiences did not indicate the presence of an interaction.(ABSTRACT TRUNCATED AT 250 WORDS)